Hydroxyethyl-Starch Solutions To Be Pulled From EU Market
Member States Can Temporarily Delay Suspension Citing Public Health Considerations
Hydroxyethyl-starch solutions are being suspended from the EU following the failure of several safety measures that were introduced to prevent their use in certain high-risk patient groups.
You may also be interested in...
The introduction of direct reporting of adverse drug reactions by patients in Europe appears to have had the desired effect: in 2013, the number of ADRs reported by patients within the European Economic Area rose by more than 50% as a result of greater public awareness of the importance of such reporting.
Italfarmaco’s HDAC inhibitor helped ambulatory Duchenne muscular dystrophy patients climb stairs faster than non-treated boys while Capricor’s cell therapy improved upper limb function in non-ambulatory patients.
FDA advisors will vote 28 June on whether an Omicron component should be included in new COVID-19 booster vaccines. Following WHO recommendations, the FDA may no longer also be looking to update the primary vaccine series at this time.